文献速递肝病

采用年龄校正的FIB-4指数与振动控制瞬时弹性成像序贯方法检测韩国非酒精性脂肪性肝病患者进展期纤维化

A sequential approach using the age-adjusted fibrosis-4 index and vibration-controlled transient elastography to detect advanced fibrosis in Korean patients with non-alcoholic fatty liver disease.
PubMed 文献 · Aliment Pharmacol Ther · 2022-01-09

本研究前瞻性纳入2014年1月至2019年12月单中心539例接受肝活检的非酒精性脂肪性肝病患者,评估振动控制瞬时弹性成像及年龄校正FIB-4序贯策略对进展期纤维化的诊断效能。结果显示肝硬度测量诊断≥F2、≥F3和F4的AUROC分别为0.82、0.92和0.95,年龄校正FIB-4联合肝硬度序贯策略分类不确定度最低(5.3%)、诊断准确率最高(81%)。

要点

  • 肝硬度测量诊断≥F2、≥F3和F4的AUROC分别为0.82、0.92和0.95。
  • 肝硬度最佳截断值:≥F2为6.7 kPa,≥F3为8.3 kPa,F4为9.8 kPa。
  • 年龄校正FIB-4联合肝硬度序贯策略不确定度5.3%、准确率81%。

核心结论

  • 年龄校正FIB-4与振动控制瞬时弹性成像序贯方法可作为检测非酒精性脂肪性肝病进展期纤维化的实用诊断策略。

研究设计与样本

  • 前瞻性收集2014年1月至2019年12月单中心539例接受肝活检的非酒精性脂肪性肝病患者数据。
  • 采用受试者工作特征曲线下面积(AUROC)评估诊断效能,并分析多种联合FIB-4评分与肝硬度测量的模型以减少不必要的肝活检。

主要发现

  • 显著纤维化(≥F2)、进展期纤维化(≥F3)和肝硬化(F4)分别为173例(32.1%)、74例(13.7%)和46例(8.5%)。
  • 肝硬度测量诊断≥F2、≥F3和F4的AUROC(95%CI)分别为0.82(0.78-0.85)、0.92(0.89-0.94)和0.95(0.93-0.97)。
  • 肝硬度最佳截断值:≥F2为6.7 kPa,≥F3为8.3 kPa,F4为9.8 kPa。
  • 肝硬度测量受腰围、血清白蛋白和纤维化分期影响(R²=0.315)。
  • 腹部肥胖、转氨酶升高、糖尿病和高IQR/Median与肝硬度测量和病理数据间≥2个纤维化分期的分歧相关。

关键数值与推荐

  • 在多种无创检测组合中,年龄校正FIB-4与肝硬度序贯使用分类疾病严重程度的不确定度最低(5.3%),诊断准确率最高(81%)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: Vibration-controlled transient elastography (VCTE) has shown good diagnostic performance in predicting fibrosis stages in patients with non-alcoholic fatty liver disease (NAFLD). However, an optimal diagnostic approach to detect advanced fibrosis in patients with NAFLD has not been established. APPROACH AND RESULTS: We prospectively collected data from 539 subjects who underwent liver biopsy at a single centre between January 2014 and December 2019. Diagnostic performance was estimated using the area under the receiver-operating characteristic curve (AUROC). Several models combining the fibrosis 4 index (FIB-4) score and liver stiffness measurement (LSM) were analysed to reduce the need for unnecessary liver biopsies. We observed significant fibrosis (≥F2), advanced fibrosis (≥F3) and cirrhosis (F4) in 173 (32.1%), 74 (13.7%) and 46 subjects (8.5%), respectively. The AUROCs (95% CI) for LSMs to diagnose ≥F2, ≥F3 and F4 were 0.82 (0.78-0.85), 0.92 (0.89-0.94) and 0.95 (0.93-0.97), respectively. Optimal LSM cut-off values were 6.7 (≥F2), 8.3 (≥F3) and 9.8 (F4) kPa. LSMs were affected by waist circumference, serum albumin and fibrosis stage (R2 = 0.315). Abdominal obesity, elevated transaminase, diabetes mellitus and high IQR/Median were associated with the discordance of ≥2 fibrosis stages between LSMs and histologic data. The sequential use of the age-adjusted FIB-4 and LSMs yielded the least uncertainty (5.3%) in classifying disease severity with the highest diagnostic accuracy (81%) among a variety of non-invasive test combinations. CONCLUSIONS: The sequential approach of age-adjusted FIB-4 and VCTE could represent a practical diagnostic strategy to detect advanced fibrosis in NAFLD (ClinicalTrials.gov #NCT02206841).

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Lee DH, Sung SU, Lee YK, et al. A sequential approach using the age-adjusted fibrosis-4 index and vibration-controlled transient elastography to detect advanced fibrosis in Korean patients with non-alcoholic fatty liver disease. Aliment Pharmacol Ther. 2022. PMID: 35005800. doi:10.1111/apt.16766

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。